Y-Intercept (HK)’s Oramed Pharmaceuticals ORMP Stock Holding History

Y-Intercept (HK)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.6K	Buy	+12,817	New	+$51K	﹤0.01%	1620

Other funds holding ORMP

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

SCM

Sage Capital Management Stockton, New Jersey $256M AUM 29.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Y-Intercept (HK)'s ORMP Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 12,817 shares worth $61.6K. The stake represents ﹤0.01% of the portfolio and ranks #1620 among its holdings.

8 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Y-Intercept (HK) held 12,817 shares of Oramed Pharmaceuticals worth $61.6K as of Q2 2026.
Oramed Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1620 holding.
8 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.